Simvastatin Coronary Atherosclerosis Trial

Posted on Posted in Completed Project

A randomized, double blind clinical trial using the lipid lowering agent, Simvastatin, and the angiotensin converting enzyme inhibitor, Enalapril, to promote regression of coronary atherosclerosis.

Contact Person:
Dr. Koon K. Teo

Publications:
1. Koon K Teo MB PhD, Jeffrey R Burton MD, Joseph DeAlmeida PEng, Shelley Dolezsar BSc, Patricia A Montague BSc, Vladimir Dzavik MD, Wayne J Tymchak MD, Dylan A Taylor MD, Terrence J Montague MD, for the Simvastatin/Enalapril Coronary Athersclerosis Trial (SCAT) Investigators. Quantitative relation of electrocardiographic and angiocardiographic measures of risk in patients with coronary atherosclerosis. Can J Cardiol 1997;13:363-369.

2. Teo KK, Burton JR, Yokoyama S, Montague TJ for the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT) Investigators. Rationale and design features of a clinical trial examining the effects of cholesterol lowering and angiotensin converting enzyme inhibition on coronary atherosclerosis. Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Can J Cardiol 1997;13:591-602.

3. Teo KK, Burton J, Buller C, Plante S, Catellier D, Tymchak W, Dzavik V, Taylor D, Yokoyama S, Montague TJ. Long-term effects of cholesterol lowering and angiotensin-converting Enzyme Inhibition on Coronary Atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation 2000;102:1748-1754.